Bial – Portela & Ca SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Bial - Portela & Ca SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10823
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ポルトガル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bial – Portela & Ca SA (BIAL) is a pharmaceutical company that discovers, develops and provides drugs for neurosciences and cardiovascular therapeutic areas. The company offers products such as anti-inflammatories, anti-diabetics, cardiovascular, anti-asthmatics, antibiotics, antidepressants and anti-anemics, among others. Its products find its application in various therapeutic areas such as antibiotic therapy, cardiovascular diseases, central nervous system, immunotherapy, musculoskeletal system, and respiratory disease. BIAL offers services such as research, development, scientific research, integrity rigor and administration of the RDI management system, among others. The company has its presence in Angola, Cote d’Ivoire, Germany, Italy, Mozambique, Panama, Poland, Spain, Switzerland, and the UK. BIAL is headquartered in Porto, Portugal.

Bial – Portela & Ca SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Bial – Portela Acquires Business Unit from Grupo Juste 10
Partnerships 11
Medigene Enters Into Co-Marketing Agreement With Bial For Veregen 11
Licensing Agreements 12
WhanIn Pharma Enters into Licensing Agreement with Bial – Portela 12
Jiangsu Wanbang Biochemical Enters into Licensing Agreement with Bial – Portela 13
Neurocrine Biosciences Enters into Licensing Agreement with Bial 14
BIAL Enters into Licensing Agreement with Helsinn 15
Bial Enters into Licensing Agreement with Moksha8 Pharma for Eslicarbazepine Acetate 16
Ono Pharma Enters Into Licensing Agreement With Bial For BIA 9-1067 17
Acquisition 18
Roxall Medizin to Acquire Bial-Aristegui from Bial – Portela & Ca 18
Bial – Portela & Ca SA – Key Competitors 19
Bial – Portela & Ca SA – Key Employees 20
Bial – Portela & Ca SA – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Key Facts 2
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bial - Portela & Ca SA, Deals By Therapy Area, 2012 to YTD 2018 8
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Bial - Portela Acquires Business Unit from Grupo Juste 10
Medigene Enters Into Co-Marketing Agreement With Bial For Veregen 11
WhanIn Pharma Enters into Licensing Agreement with Bial - Portela 12
Jiangsu Wanbang Biochemical Enters into Licensing Agreement with Bial - Portela 13
Neurocrine Biosciences Enters into Licensing Agreement with Bial 14
BIAL Enters into Licensing Agreement with Helsinn 15
Bial Enters into Licensing Agreement with Moksha8 Pharma for Eslicarbazepine Acetate 16
Ono Pharma Enters Into Licensing Agreement With Bial For BIA 9-1067 17
Roxall Medizin to Acquire Bial-Aristegui from Bial - Portela & Ca 18
Bial - Portela & Ca SA, Key Competitors 19
Bial - Portela & Ca SA, Key Employees 20
Bial - Portela & Ca SA, Subsidiaries 21

List of Figures
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Bial – Portela & Ca SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Toho Holdings Co Ltd (8129):企業の財務・戦略的SWOT分析
    Toho Holdings Co Ltd (8129) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Kaiser Foundation Health Plan Inc:企業の戦略的SWOT分析
    Kaiser Foundation Health Plan Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • University of Cape Town-製薬・医療分野:企業M&A・提携分析
    Summary University of Cape Town (UCT) is a public research university that offers educational services. The university offers services for faculty of commerce, faculty of engineering and the built environment, faculty of health sciences, faculty of humanities, faculty of law and faculty of science. …
  • Protokinetix Inc (PKTX):製薬・医療:M&Aディール及び事業提携情報
    Summary ProtoKinetix Inc (ProtoKinetix) is a biotechnology company that develops solutions for cell survival and health. The company develops anti-aging glycopeptides used to protect cell lines including hela cells, neonatal fibroblasts, adult fibroblast, human neuronal stem cells, CD34+ cells and k …
  • Svenska Petroleum Exploration AB:石油・ガス:M&Aディール及び事業提携情報
    Summary Svenska Petroleum Exploration AB (Svenska Petroleum), a subsidiary of Petroswede AB is an oil and gas company that offers offshore oil exploration and production. The company operates 3D Sendji data and acquisition of new 3D data in Kaba area to explore for the pre-salt. It has oil and gas p …
  • Nuevolution AS-製薬・医療分野:企業M&A・提携分析
    Summary Nuevolution A/S (Nuevolution), a subsidiary of Nuevolution AB, is a biopharmaceutical company that develops treatments for cancer and chronic inflammatory diseases. It focuses on developing drugs for the treatment of chronic inflammatory diseases such as rheumatoid arthritis, psoriasis; onco …
  • Ducommun Incorporated:戦略・SWOT・企業財務分析
    Ducommun Incorporated - Strategy, SWOT and Corporate Finance Report Summary Ducommun Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Goodfellow Inc (GDL):企業の財務・戦略的SWOT分析
    Goodfellow Inc (GDL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development-製薬・医療分野:企業M&A・提携分析
    Summary Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a subsidiary of National Institutes of Health is a research institute that conducts and supports laboratory research, clinical trials, and epidemiological studies. The institute conducts research in the …
  • Dabur India Ltd (DABUR):企業の財務・戦略的SWOT分析
    Dabur India Ltd (DABUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Endeavour Mining Corporation:企業の戦略・SWOT・財務情報
    Endeavour Mining Corporation - Strategy, SWOT and Corporate Finance Report Summary Endeavour Mining Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Fluidigm Corp (FLDM)-製薬・医療分野:企業M&A・提携分析
    Summary Fluidigm Corp (Fluidigm) formerly known as Mycometrix Corporation, is a biotechnology company which manufactures life-science tools and creates technologies based on microfluidics and mass cytometry. The company’s products systems include biomark HD system, access array system, C1 system, ca …
  • MediaValet Inc.:戦略・SWOT・企業財務分析
    MediaValet Inc. - Strategy, SWOT and Corporate Finance Report Summary MediaValet Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Shilpa Medicare Ltd (SHILPAMED):製薬・医療:M&Aディール及び事業提携情報
    Summary Shilpa Medicare Ltd (Shilpa Medicare) focuses on the development, manufacture and commercialization of generic pharmaceutical products and active pharmaceutical ingredients (APIs). It offers medicines for the treatment of cancer, infectious diseases such as HIV, multiple sclerosis and immuno …
  • WebMD Health Corp:企業の戦略的SWOT分析
    WebMD Health Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • MAXONS Restorations Inc:企業の戦略的SWOT分析
    MAXONS Restorations Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Braskem SA (BRKM5):企業の財務・戦略的SWOT分析
    Braskem SA (BRKM5) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Uber Technologies Inc:企業の戦略・SWOT・財務情報
    Uber Technologies Inc - Strategy, SWOT and Corporate Finance Report Summary Uber Technologies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • The Ultimate Software Group Inc (ULTI):企業の財務・戦略的SWOT分析
    The Ultimate Software Group Inc (ULTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Majesco
    Majesco - Strategy, SWOT and Corporate Finance Report Summary Majesco - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆